Hengrui Pharmaceutical (600276.SH): Some drugs have obtained drug clinical trial approval notices

Zhitongcaijing · 05/09 10:01

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue “Clinical Pharmaceuticals for Adabelimab injections, SHR-8068 injections, bevacizumab injections, SHR-1826 for injections, SHR-A1904 for injections, and SHR-A2102 for injections “Trial Approval Notice”. Clinical trials will be carried out in the near future.

According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, the clinical trial applications for adbelimab injection, SHR-8068 injection, bevacizumab injection, SHR-1826, injectable SHR-A1904, injectable SHR-A2009, and injectable SHR-A2102 met the relevant requirements of drug registration and agreed to carry out this study. Specifically: The safety, tolerability and efficacy of adbelimab in combination with other anti-tumor treatments in solid tumor subjects The center opens phase II clinical research.